The United States Agency for International Development (USAID) is seeking input through a Sources Sought/Request for Information (RFI) regarding Innovations in Malaria Vaccines and Biologics Development (IMVB). The primary objective is to gather insights from small businesses capable of supporting the development of malaria vaccines and monoclonal antibodies (mAbs) that effectively target the Plasmodium falciparum parasite, addressing critical challenges such as drug resistance and vaccine efficacy. This initiative is part of USAID's commitment to enhancing malaria health solutions through strategic partnerships and innovative research, with a projected budget of $25-50 million over a span of 5 to 10 years. Interested parties are encouraged to provide organizational capacity information and feedback on the technical design outlined in the DRAFT SECTION C attachment, and can reach out to the primary contact, IMVB, at imvb@usaid.gov or the secondary contact, Natalia Kornilova, at nkornilova@usaid.gov for further details.